TG Therapeutics (TGTX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

TGTX Stock Forecast


TG Therapeutics stock forecast is as follows: an average price target of $23.75 (represents a -26.91% downside from TGTX’s last price of $32.49) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

TGTX Price Target


The average price target for TG Therapeutics (TGTX) is $23.75 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $27.50 to $20.00. This represents a potential -26.91% downside from TGTX's last price of $32.49.

TGTX Analyst Ratings


Buy

According to 7 Wall Street analysts, TG Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TGTX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

TG Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Edward WhiteH.C. Wainwright$27.50$12.93112.68%-15.37%
Aug 06, 2024Corinne JenkinsGoldman Sachs$20.00$20.58-2.82%-38.45%
May 03, 2024Edward WhiteH.C. Wainwright$24.50$8.21198.42%-24.60%
Feb 07, 2023Cantor Fitzgerald$24.00$18.4829.87%-26.14%
Dec 30, 2022Evercore ISI$16.00$11.8335.25%-50.76%
Dec 29, 2022Edward WhiteH.C. Wainwright$12.00$4.23183.69%-63.07%
Apr 19, 2022Goldman Sachs$5.00$7.26-31.13%-84.61%
Apr 18, 2022Mayank MamtaniTelsey Advisory$11.50$3.46232.37%-64.61%

The latest TG Therapeutics stock forecast, released on Nov 05, 2024 by Edward White from H.C. Wainwright, set a price target of $27.50, which represents a 112.68% increase from the stock price at the time of the forecast ($12.93), and a -15.37% decrease from TGTX last price ($32.49).

TG Therapeutics Price Target by Period


1M3M12M
# Anlaysts-13
Avg Price Target-$27.50$24.00
Last Closing Price$32.49$32.49$32.49
Upside/Downside-100.00%-15.37%-26.14%

In the current month, the average price target of TG Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TG Therapeutics's last price of $32.49. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2024H.C. WainwrightBuyBuyHold
Oct 29, 2024Cowen & Co.BuyInitialise
Oct 24, 2024B. RileyBuyBuyHold
Sep 18, 2024H.C. WainwrightBuyBuyHold
Aug 06, 2024Goldman SachsNeutralNeutralHold
May 03, 2024H.C. WainwrightBuyBuyHold
Aug 02, 2023Goldman SachsSellNeutralUpgrade
Dec 30, 2022JefferiesBuyBuyHold
Dec 30, 2022Goldman SachsSellSellHold
Dec 30, 2022Evercore ISIOutperformOutperformHold
Dec 30, 2022B. Riley SecuritiesBuyBuyHold
Dec 29, 2022B. RileyBuyBuyHold
Dec 29, 2022Morgan StanleyUnderperformUnderperformHold
Dec 29, 2022H.C. WainwrightBuyBuyHold

TG Therapeutics's last stock rating was published by H.C. Wainwright on Oct 29, 2024. The company gave TGTX a "Buy" rating, the same as its previous rate.

TG Therapeutics Financial Forecast


TG Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Revenue--------$43.97M$165.81M$16.07M$7.80M$80.00K$94.00K$594.00K$2.02M$2.32M$2.03M$1.54M$793.00K$38.00K$38.00K$38.00K$38.00K$38.00K$38.00K$38.00K$38.00K
Avg Forecast$172.50M$144.77M$128.56M$112.93M$98.26M$81.70M$65.92M$54.60M$40.06M$23.91M$17.39M$3.38M$1.60M$1.46M$175.43K$2.08M$2.24M$2.97M$3.60M$820.29K$19.00K$19.00K$22.80K$22.80K$22.80K$34.50K$19.00K$25.33K
High Forecast$181.17M$152.04M$135.02M$117.68M$103.75M$81.94M$65.92M$54.60M$40.18M$23.91M$18.27M$3.55M$1.68M$1.46M$175.43K$2.08M$2.24M$2.97M$3.60M$820.29K$19.00K$19.00K$22.80K$22.80K$22.80K$34.50K$19.00K$25.33K
Low Forecast$165.47M$138.86M$123.32M$108.17M$95.30M$81.47M$65.92M$54.60M$39.88M$23.91M$16.68M$3.24M$1.54M$1.46M$175.43K$2.08M$2.24M$2.97M$3.60M$820.29K$19.00K$19.00K$22.80K$22.80K$22.80K$34.50K$19.00K$25.33K
# Analysts1112544454443333444444443333
Surprise %--------1.10%6.93%0.92%2.31%0.05%0.06%3.39%0.97%1.04%0.68%0.43%0.97%2.00%2.00%1.67%1.67%1.67%1.10%2.00%1.50%

TG Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $54.60M, with a low forecast of $54.60M, and a high forecast of $54.60M. TGTX's average Quarter revenue forecast represents a 24.18% increase compared to the company's last Quarter revenue of $43.97M (Dec 23).

TG Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1112544454443333444444443333
EBITDA--------$-12.48M$114.78M$-43.98M$-36.39M$-50.13M$-34.04M$-37.49M$-66.22M$-92.18M$-84.52M$-76.81M$-88.67M$-86.87M$-85.51M$-50.62M$-49.88M$-37.65M$-60.37M$-35.11M$-35.13M
Avg Forecast$-134.15M$-112.58M$-99.98M$-87.82M$-76.42M$-63.54M$-51.27M$-42.46M$-31.16M$-18.60M$-13.53M$-2.63M$-1.25M$-1.14M$-137.18K$-49.39M$-1.75M$-2.32M$-2.82M$-57.73M$-14.86K$-66.09M$-17.83K$-17.83K$-17.83K$-26.98K$-14.86K$-19.81K
High Forecast$-128.68M$-107.99M$-95.90M$-84.12M$-74.11M$-63.36M$-51.27M$-42.46M$-31.02M$-18.60M$-12.97M$-2.52M$-1.20M$-1.14M$-137.18K$-39.51M$-1.75M$-2.32M$-2.82M$-46.18M$-14.86K$-52.87M$-17.83K$-17.83K$-17.83K$-26.98K$-14.86K$-19.81K
Low Forecast$-140.89M$-118.24M$-105.00M$-91.52M$-80.68M$-63.72M$-51.27M$-42.46M$-31.25M$-18.60M$-14.20M$-2.76M$-1.31M$-1.14M$-137.18K$-59.26M$-1.75M$-2.32M$-2.82M$-69.27M$-14.86K$-79.30M$-17.83K$-17.83K$-17.83K$-26.98K$-14.86K$-19.81K
Surprise %--------0.40%-6.17%3.25%13.85%40.19%29.90%273.31%1.34%52.63%36.42%27.25%1.54%5847.34%1.29%2839.31%2797.97%2111.45%2237.64%2363.40%1773.59%

5 analysts predict TGTX's average Quarter EBITDA for Dec 23 to be $-31.16M, with a high of $-31.02M and a low of $-31.25M. This is -127.14% lower than TG Therapeutics's previous annual EBITDA (Sep 23) of $114.78M.

TG Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1112544454443333444444443333
Net Income--------$-14.42M$113.93M$-47.61M$-38.63M$-53.92M$-36.67M$-42.08M$-71.15M$-93.73M$-86.15M$-79.50M$-92.05M$-89.65M$-88.60M$-54.92M$-51.99M$-41.18M$-63.00M$-36.88M$-35.62M
Avg Forecast$61.15M$46.85M$36.77M$25.06M$13.09M$4.82M$-7.33M$-9.64M$-16.11M$9.19M$-40.42M$-58.26M$-43.57M$-56.60M$-76.52M$-51.45M$-101.23M$-90.87M$-82.90M$-59.00M$-95.43M$-67.36M$-53.89M$-57.07M$-73.02M$-53.81M$-64.83M$-69.35M
High Forecast$65.15M$49.91M$39.17M$26.69M$20.57M$5.14M$-6.94M$-9.13M$-13.43M$9.79M$-38.27M$-55.17M$-41.26M$-56.60M$-76.52M$-41.16M$-101.23M$-90.87M$-82.90M$-47.20M$-95.43M$-53.89M$-53.89M$-57.07M$-73.02M$-53.81M$-64.83M$-69.35M
Low Forecast$57.91M$44.36M$34.82M$22.27M$11.22M$4.57M$-7.81M$-10.27M$-17.46M$8.70M$-43.06M$-62.06M$-46.42M$-56.60M$-76.52M$-61.74M$-101.23M$-90.87M$-82.90M$-70.80M$-95.43M$-80.83M$-53.89M$-57.07M$-73.02M$-53.81M$-64.83M$-69.35M
Surprise %--------0.89%12.40%1.18%0.66%1.24%0.65%0.55%1.38%0.93%0.95%0.96%1.56%0.94%1.32%1.02%0.91%0.56%1.17%0.57%0.51%

TG Therapeutics's average Quarter net income forecast for Dec 23 is $-16.11M, with a range of $-17.46M to $-13.43M. TGTX's average Quarter net income forecast represents a -114.14% decrease compared to the company's last Quarter net income of $113.93M (Sep 23).

TG Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1112544454443333444444443333
SG&A--------$31.15M$26.50M$36.38M$29.65M$28.26M$17.50M$14.97M$22.50M$56.46M$34.90M$34.02M$26.76M$43.86M$35.30M$14.43M$14.26M$7.06M$2.91M$2.72M$2.34M
Avg Forecast$34.21B$28.71B$25.50B$22.40B$19.49B$16.20B$13.07B$10.83B$7.95B$4.74B$3.45B$670.15M$318.16M$288.71M$34.79M$412.66M$444.22M$588.55M$714.97M$162.69M$3.77M$3.77M$4.52M$4.52M$4.52M$6.84M$3.77M$5.02M
High Forecast$35.93B$30.15B$26.78B$23.34B$20.58B$16.25B$13.07B$10.83B$7.97B$4.74B$3.62B$703.83M$334.15M$288.71M$34.79M$412.66M$444.22M$588.55M$714.97M$162.69M$3.77M$3.77M$4.52M$4.52M$4.52M$6.84M$3.77M$5.02M
Low Forecast$32.82B$27.54B$24.46B$21.45B$18.90B$16.16B$13.07B$10.83B$7.91B$4.74B$3.31B$642.81M$305.18M$288.71M$34.79M$412.66M$444.22M$588.55M$714.97M$162.69M$3.77M$3.77M$4.52M$4.52M$4.52M$6.84M$3.77M$5.02M
Surprise %--------0.00%0.01%0.01%0.04%0.09%0.06%0.43%0.05%0.13%0.06%0.05%0.16%11.64%9.37%3.19%3.15%1.56%0.43%0.72%0.47%

TG Therapeutics's average Quarter SG&A projection for Mar 24 is $10.83B, based on 4 Wall Street analysts, with a range of $10.83B to $10.83B. The forecast indicates a 34662.49% rise compared to TGTX last annual SG&A of $31.15M (Dec 23).

TG Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1112544454443333444444443333
EPS--------$-0.10$0.80$-0.34$-0.28$-0.39$-0.27$-0.31$-0.53$-0.71$-0.65$-0.60$-0.70$-0.72$-0.74$-0.49$-0.49$-0.43$-0.70$-0.42$-0.44
Avg Forecast$0.38$0.29$0.23$0.16$0.08$0.03$-0.05$-0.06$-0.10$0.06$-0.25$-0.36$-0.27$-0.35$-0.48$-0.61$-0.64$-0.57$-0.52$-0.56$-0.60$-0.41$-0.34$-0.36$-0.46$-0.34$-0.41$-0.43
High Forecast$0.41$0.31$0.24$0.17$0.13$0.03$-0.04$-0.06$-0.08$0.06$-0.24$-0.34$-0.26$-0.35$-0.48$-0.61$-0.64$-0.57$-0.52$-0.56$-0.60$-0.41$-0.34$-0.36$-0.46$-0.34$-0.41$-0.43
Low Forecast$0.36$0.28$0.22$0.14$0.07$0.03$-0.05$-0.06$-0.11$0.05$-0.27$-0.39$-0.29$-0.35$-0.48$-0.61$-0.64$-0.57$-0.52$-0.56$-0.60$-0.41$-0.34$-0.36$-0.46$-0.34$-0.41$-0.43
Surprise %--------1.00%14.00%1.35%0.77%1.44%0.76%0.65%0.87%1.12%1.14%1.15%1.26%1.20%1.79%1.45%1.37%0.94%2.07%1.03%1.01%

According to 5 Wall Street analysts, TG Therapeutics's projected average Quarter EPS for Dec 23 is $-0.10, with a low estimate of $-0.11 and a high estimate of $-0.08. This represents a -112.53% decrease compared to TGTX previous annual EPS of $0.80 (Sep 23).

TG Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.52$70.0013361.54%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
PDSBPDS Bio$1.96$9.00359.18%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
BTAIBioXcel Therapeutics$0.39$1.00156.41%Buy
VKTXViking Therapeutics$46.70$97.80109.42%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
EXELExelixis$34.69$30.89-10.95%Buy
TGTXTG Therapeutics$33.57$23.75-29.25%Buy

TGTX Forecast FAQ


Is TG Therapeutics a good buy?

Yes, according to 7 Wall Street analysts, TG Therapeutics (TGTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of TGTX's total ratings.

What is TGTX's price target?

TG Therapeutics (TGTX) average price target is $23.75 with a range of $20 to $27.5, implying a -26.91% from its last price of $32.49. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will TG Therapeutics stock go up soon?

According to Wall Street analysts' prediction for TGTX stock, the company can go down by -26.91% (from the last price of $32.49 to the average price target of $23.75), down by -15.37% based on the highest stock price target, and down by -38.45% based on the lowest stock price target.

Can TG Therapeutics stock reach $50?

TGTX's average twelve months analyst stock price target of $23.75 does not support the claim that TG Therapeutics can reach $50 in the near future.

What are TG Therapeutics's analysts' financial forecasts?

TG Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $300.49M (high $306.21M, low $297.3M), average EBITDA is $-234M (high $-231M, low $-238M), average net income is $936.64K (high $9.63M, low $-2.298M), average SG&A $59.6B (high $60.73B, low $58.96B), and average EPS is $0.00583 (high $0.0599, low $-0.0143). TGTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $558.76M (high $585.92M, low $535.82M), average EBITDA is $-435M (high $-417M, low $-456M), average net income is $169.82M (high $180.91M, low $159.36M), average SG&A $110.82B (high $116.2B, low $106.27B), and average EPS is $1.06 (high $1.13, low $0.992).

Did the TGTX's actual financial results beat the analysts' financial forecasts?

Based on TG Therapeutics's last annual report (Dec 2023), the company's revenue was $233.66M, beating the average analysts forecast of $84.75M by 175.71%. Apple's EBITDA was $20.63M, missing the average prediction of $-65.906M by -131.31%. The company's net income was $12.67M, missing the average estimation of $-106M by -112.00%. Apple's SG&A was $122.71M, missing the average forecast of $16.81B by -99.27%. Lastly, the company's EPS was $0.0853, missing the average prediction of $-0.657 by -112.98%. In terms of the last quarterly report (Dec 2023), TG Therapeutics's revenue was $43.97M, beating the average analysts' forecast of $40.06M by 9.75%. The company's EBITDA was $-12.485M, missing the average prediction of $-31.156M by -59.93%. TG Therapeutics's net income was $-14.416M, missing the average estimation of $-16.115M by -10.54%. The company's SG&A was $31.15M, missing the average forecast of $7.95B by -99.61%. Lastly, the company's EPS was $-0.1, missing the average prediction of $-0.1 by -0.27%